Two-dimensional FeCu-metal-organic-framework boosts peroxidase activity for antibacterial application
Yixuan Lu , Yaru Guo , Xiaohua Guo , Shihan Zhang , Fangyong Liu , Shuai Ding , Dandan Wang , Yanpei Wang , Kongliang Li , Yuchen Wang , Youxing Liu , Xuliang Deng
Dental Research ›› 2026, Vol. 1 ›› Issue (1) : 30 -40.
The overuse of antibiotics has led to the emergence of drug-resistant bacteria, posing a serious threat to human health and increasing the medical burden. Metal-organic frameworks (MOFs) have shown great potential as enzyme mimics for antibacterial applications; however, their performance is often limited by the low density and poor accessibility of active sites. Herein, we report an innovative surface-active agent intercalation-assisted confinement growth strategy for constructing two-dimensional (2D) NH2-BDC-Cu, Fe nanosheets (NSs) with highly exposed active site to enhance reactive oxygen species (ROS) generation, thereby improving the antibacterial efficiency against drug-resistant bacteria. We demonstrate that the synthesized 2D NH2-BDC-Cu, Fe NSs exhibit 6.6-fold higher ROS production compared to NH2-BDC-Cu, Fe nanopowders (NPs). Consequently, NH2-BDC-Cu, Fe NSs achieve 100% antibacterial activity against both Staphylococcus aureus and Escherichia coli within 1 h, markedly outperforming NH2-BDC-Cu, Fe NPs and previously reported biomaterials. Moreover,in vivo experiments confirm that NH2-BDC-Cu, Fe NSs accelerate wound healing, achieving a 100% healing rate within 10 days, which is substantially higher than that of NH2-BDC-Cu, Fe NPs. Overall, this work introduces a novel and efficient strategy for fabricating 2D MOF nanoenzymes with high active-site exposure, offering great promise for the development of advanced biomaterial-based antibacterial therapies.
Metal-organic frameworks / Two-dimensional / Self-assembly / Antibacterial / Wound healing
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
/
| 〈 |
|
〉 |